4.7 Article

Binary MoS2 nanostructures as nanocarriers for amplification in multiplexed electrochemical immunosensing: simultaneous determination of B cell activation factor and proliferation-induced signal immunity-related cytokines

Journal

MICROCHIMICA ACTA
Volume 189, Issue 4, Pages -

Publisher

SPRINGER WIEN
DOI: 10.1007/s00604-022-05250-4

Keywords

Dual immunoplatform; BAFF; APRIL; MoS2/MWCNTs; Amperometry; Serum; SLE; CRC

Funding

  1. Spanish Ministerio de Ciencia, Innovacion y Universidades [PRE2019-087,596, RTI2018-096,135-B-I00]
  2. Spanish Ministerio de Ciencia e Innovacion [PID2019-103899RB-I00]
  3. TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid [S2018/NMT-4349]
  4. AES-ISCIII program [PI17CIII/00045, PI20CIII/00019]
  5. Spanish Ministerio de Educacion, Cultura y Deporte
  6. Flanders Research Foundation (FWO) [1193818 N]
  7. CRUE-CSIC agreement
  8. Springer Nature

Ask authors/readers for more resources

A dual immunosensor was developed for the simultaneous determination of two important immunity-related cytokines, BAFF and APRIL. The immunosensor showed high sensitivity and low detection limits, making it suitable for detecting these cytokines in cancer cell lysates and serum samples.
A dual immunosensor is reported for the simultaneous determination of two important immunity-related cytokines: BAFF (B cell activation factor) and APRIL (a proliferation-induced signal). Sandwich-type immunoassays with specific antibodies (cAbs) and a strategy for signal amplification based on labelling the detection antibodies (dAbs) with binary -MoS2/ MWCNTs nanostructures and using horseradish peroxidase (HRP) were implemented. Amperometric detection was carried out at screen-printed dual carbon electrodes (SPdCEs) through the hydroquinone HQ/H2O2 system. The developed dual immunosensor provided limit of detection (LOD) of 0.08 and 0.06 ng-mL(-1) for BAFF and APRIL, respectively, and proved to be useful for the determination of both cytokines in cancer cell lysates and serum samples from patients diagnosed with autoimmune diseases and cancer. The obtained results agreed with those found using ELISA methodologies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available